Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02313987
Other study ID # Endo-EndoGET-001
Secondary ID
Status Withdrawn
Phase N/A
First received December 8, 2014
Last updated February 23, 2016
Start date June 2015
Est. completion date December 2018

Study information

Verified date February 2016
Source Itamar-Medical, Israel
Contact n/a
Is FDA regulated No
Health authority Israel: Ethics CommissionUnited States: Institutional Review BoardUnited Kingdom: National Health Service
Study type Observational

Clinical Trial Summary

The current study is designed to test the hypothesis that compared to conventional treatment; endothelial function-guided treatment reduces adverse cardiovascular events in patients with non-obstructive coronary artery disease documented at clinically indicated coronary angiography.


Description:

Subjects with chest pain and non-obstructive coronary artery disease (20-70% luminal diameter narrowing) documented by coronary angiograms will be enrolled in the study 2 - 30 days following the coronary angiograms. Only subjects who have signed an Informed Consent Form and meet all of the eligibility criteria will be qualified for enrollment.

Following the baseline EndoPAT testing subjects will be divided into two groups by their EndoPAT (EndoScore) results:

1. Group A - normal EndoScore: Logarithmic value of RHI (Ln_RHI) >0.7

2. Group B - abnormal EndoScore: Ln_RHI ≤ 0.7 The subjects of Group B will be randomized in 1:1 ratio (by envelopes with randomization numbers at each site) to Group B1 who will be treated conventionally i.e., "usual care" by the site study team; and Group B2 who will be treated with "enhanced care".

Staff prescribing treatment regime for subjects in group A and B1 ("usual care") along with the subjects in these groups, will be blinded to the EndoScore value.

Subjects of all groups will return for 4 follow-up visits: 180±14days, 360±14days, 720±14days and 1080±14days (study end).


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 2018
Est. primary completion date June 2018
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 79 Years
Eligibility Inclusion Criteria:

- Subjects with chest pain and non-obstructive coronary artery disease documented by coronary angiography with 20-70% luminal diameter stenosis that does not justify coronary revascularization

- Stable subjects without evidence of prior MI/CABG/PTCA.

- Age 20 to 79 years

- Ability to understand the study procedures and provide written informed consent

- Willingness and ability to comply with the study and its scheduled visits and study procedures

Exclusion Criteria:

- Age below 20 over 79 years

- Subjects with documented MI, PTCA or CABG

- Unstable angina

- Any lesion > 20% luminal narrowing in the left main coronary artery

- Congestive heart failure, NYHA class II - IV

- Severe renal dysfunction, defined as an estimated glomerular filtration rate (eGFR calculated by MDRD) < 20 mL/min/1.73m2 at screening

- Uncontrolled hyperthyroidism or hypothyroidism as defined by thyroid stimulating hormone (TSH) , 1.0 time the lower limit of normal (LLN) or > 1.5 times the upper limit of normal (ULN), respectively, at screening

- Symptomatic peripheral artery disease

- History of drug or alcohol abuse

- Active liver disease or hepatic dysfunction, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) 2 times the ULN as determined by local laboratory analysis at screening

- Prior CVA or TIA

- Malignancy (except non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in situ or stage 1 prostate carcinoma) with life expectancy of < 3 years

- Any planned surgery within 3 months after randomization

- Recipient of any major organ transplant (e.g., heart, lung, liver, bone marrow)

- Severe, concomitant non-cardiovascular disease that is expected to reduce life expectancy to less than 3 years

- Known, concerning active infection or major hematologic, renal, metabolic, gastrointestinal or endocrine dysfunction in the judgment of the investigator

- Currently enrolled in another investigational device or drug study, or less than 30 days since ending another investigational device or drug study(s), or receiving other investigational agent(s). Special clearance can be obtained from the Steering Committee for subjects enrolled in studies not conflicting with this protocol

- History or evidence of any other clinically significant disorder, condition or disease other than those outlined above that, in the opinion of the investigator may compromise the ability of the subject to give written informed consent, would pose a risk to the subject safety, or interfere with the study evaluation, procedures or completion

- Deformities of the digits of the upper extremities, which preclude adequate signal acquisition

- Subjects under the effect of short-acting NTG (3 hours washout period)

- Patient suffering from a medical condition prohibiting blood flow occlusion in both arms

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Locations

Country Name City State
Israel Meir Hospital Kfar Saba
Israel Tel Hashomer Ramat Gan

Sponsors (1)

Lead Sponsor Collaborator
Itamar-Medical, Israel

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary MACE Time to the first occurrence of death, cardiovascular death, non-fatal myocardial infarction, stroke, transient ischemic attack, coronary revascularization, or hospitalization for congestive heart failure. 3 years No
Secondary Rehospitalization for chest pain 3 years No
Secondary quality of life questionnaire 3years No
Secondary time to the first occurrence of cardiovascular death 3 years No
Secondary myocardial infarction 3 years No
Secondary Stroke 3 years No
Secondary time to the first occurrence of death from any cause 3 years No
Secondary hospitalization for worsening heart failure 3 years No
Secondary time to the first occurrence of ischemic fatal or non-fatal stroke or transient ischemic attack. 3 years No
See also
  Status Clinical Trial Phase
Completed NCT02335086 - DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease N/A
Withdrawn NCT02265146 - ORACLE-NIRS: Lipid cORe Plaque Association With CLinical Events: a Near-InfraRed Spectroscopy Study
Completed NCT00811772 - Trial of Drug Eluting Stent Versus Bare Metal Stent to Treat Coronary Artery Stenosis N/A
Recruiting NCT03322332 - Adipokines of Epicardial Adipose Tissue and Atherosclerosis of Coronary Arteries N/A
Completed NCT02305953 - Cytokines and Vascular Inflammation in Psoriasis N/A
Completed NCT01642173 - Assessment of Coronary Plaque Composition Using Optical Coherence Tomography Phase 1
Completed NCT02316782 - Bifurcation Lesion Analysis and STenting / BLAST
Completed NCT00548613 - Combination Stem Cell (MESENDO) Therapy for Utilization and Rescue of Infarcted Myocardium Phase 1
Terminated NCT00243308 - Serp-1 for the Treatment of Acute Coronary Syndrome Phase 2
Recruiting NCT05105750 - A Comparative Study of Indobufen and Aspirin in Patients With Coronary Atherosclerosis Phase 4
Completed NCT01722214 - Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis Phase 4
Terminated NCT01030328 - AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis Phase 3
Suspended NCT00790764 - Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI) Phase 2
Active, not recruiting NCT01061398 - CT-FIRST: Cardiac Computed Tomography Versus Stress Imaging For Initial Risk STratification N/A
Completed NCT00431717 - Coronary Computed Tomography Angiography and SPECT in Asymptomatic Diabetes N/A
Completed NCT00431977 - Validation Study of Coronary CT Angiography as a Screening Tool in Asymptomatic Diabetes N/A
Recruiting NCT00155350 - Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients Phase 4
Recruiting NCT05708547 - Role of Mitophagy in Myeloid Cells During Coronary Atherosclerosis.
Terminated NCT02440646 - Natural History of Coronary Atherosclerosis in Real-World Stable Chest Pain Patients Underwent Computed Tomography Angiography in Comparison With Invasive Multimodality Imaging
Terminated NCT01268319 - CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow N/A